All In Biotech

Drug Trial Radar · NCT04711135

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL)

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

11

Actual

Start

Aug 31, 2022

Primary completion

Mar 12, 2024

Study completion Feb 6, 2034

Sponsor

Lead sponsor
Advanced Accelerator ApplicationsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumors
  • Pheochromocytoma
  • Paraganglioma

Interventions

  • Lutetium [177Lu] oxodotreotide/dotatateDrug

    Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absorbed Radiation Doses in Target OrganTime frame: Up to 8 days after the first Lutetium [Lu 177] dotatate dose
  2. Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera AdministrationTime frame: during first cycle of Lutetium [Lu 177] dotatate treatment (Cycle = 56 days)

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Kentucky

    Lexington, Kentucky

  • Cincinnati Children's Hospital

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Centre Léon Berard

    Lyon, France

  • Maria Sklodowska-Curie National Research Institute of Oncology

    Gliwice, Poland

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • University College Hospital of London

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.